MedTrace Logo

Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male

NCT03083990 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-11-27

Study results available
· View outcomes & findings →

Summary

To confirm the PK similarity of IBI305 and bevacizumab in healthy volunteers .

Conditions

  • Healthy

Interventions

BIOLOGICAL

IBI305(Bevacizumab Biosimilar)

3mg/kg, infusion in 90minutes

DRUG

Avastin(Bevacizumab)

3mg/kg, infusion in 90minutes

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • yanhua Ding, Doctor · Jilin University First Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-09
Primary Completion
2017-08-17
Completion
2017-08-17

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03083990 on ClinicalTrials.gov